Trial Profile
Phase II Study to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Histamine dihydrochloride (Primary)
- Indications Migraine with aura; Migraine without aura
- Focus Therapeutic Use
- Sponsors BioHealthonomics
- 18 Jul 2022 Planned primary completion date changed from 1 Sep 2016 to 1 Jul 2023.
- 18 Jul 2022 Planned initiation date changed from 1 Sep 2015 to 1 Oct 2022.
- 26 Jan 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov record.